Decision spine
Frames the controlling thesis, evidence status, buyer implications, and research-use limits.
Infectious Disease
Zemi Dossier
Research-use only
Precision AMR Countermeasures
A decision package on cornering antimicrobial resistance through diagnostics, combination logic, microbiome sparing, and durability-aware countermeasure design.
Decision this dossier helps answer
Which AMR countermeasures reduce escape paths enough to justify development, deployment, or monitoring priority?
Problem this dossier solves
Durability comes from cornering escape, not just adding potency.
The dossier turns AMR strategy into a resistance-accounting problem: surviving inoculum, independent escape steps, diagnostic delay, and collateral selection pressure. It helps buyers see which countermeasures actually shrink the evolutionary path.
What is moving: current field evidence and platform activity
What is unresolved: decision-grade proof, endpoint logic, and failure modes
What Zemi solves: evidence-gated next-study strategy
Full decision package
118-page research report plus 36-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
Durability comes from cornering escape, not just adding potency.
The dossier turns AMR strategy into a resistance-accounting problem: surviving inoculum, independent escape steps, diagnostic delay, and collateral selection pressure. It helps buyers see which countermeasures actually shrink the evolutionary path.
A Zemi Dossier turns uncertain emerging research into a decision package: what is known, what is inferred, what is hypothetical, what would falsify the thesis, and what should be built, funded, avoided, monitored, or validated next.
Research report preview
First 30 pages of the actual Precision AMR Countermeasures research report.
The public page shows the real document style, density, evidence posture, and decision framing before a buyer requests access to the full Zemi Dossier package.
Research report
The research report is the argument. It is not the whole product.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Inspectable infrastructure
Pairs the report with claim ledgers, evidence tables, power rows, audit surfaces, and decision tools.
Executable next studies
Links hypotheses to endpoint logic, assumptions, sample-size logic, budget, and timeline planning.
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Evidence License | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Lets the buyer audit support strength before relying on the package. |
| Evidence License (read first) | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Lets the buyer audit support strength before relying on the package. |
| Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Brief Read First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Brief: Read This First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Scope and Evidence Integrity | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Scope and Evidence-Integrity Statement | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Decision Snapshot Overview | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Snapshot | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Cheat Sheet | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Cheat Sheet | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buy Build Wait Avoid | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buy / Build / Wait / Avoid - and the Buyer Decision Dashboard | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| Source-Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| Resistance Cornering Model | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Resistance-Cornering Stack: the controlling model | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Six layers, one product | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The law that makes the stack generative | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The caveat that disciplines the law: corner the verified trade-off, not the theoretical one | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The flagship architecture the model implies: a diagnosis-linked, resistance-aware closed loop | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The model validated from the outside | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The sharpening: from a layered taxonomy to the Mutational-Supply Ledger | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Ledger as six falsifiable Laws (each with the result that would refute it) | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The novel instrument the Laws imply: the proposed k-integrity workflow (a prototype assay) | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Resistance Cornering Classifier | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The Resistance-Cornering Classifier (RCC): a reusable decision model | Defines the governing argument and the evidence gates that would support or falsify it. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Current Signal Update 2025 2026 | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| June-2026 Current-Signal Refresh | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The single-agent approval wave (the natural experiment) | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Diagnostics, microbiome, and the two flagship nulls | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The cornering frontier hardened | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Capital and policy moved - toward the wrong term | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Capital Policy Landscape 2026 | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The 2026 Capital and Policy Landscape | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross Layer Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
Evidence & Decision Workbook
The workbook is the decision engine.
A locked public preview of selected workbook-derived sheets: sheet structure, decision modules, power rows, traceability, and audit posture. Licensed buyers receive the full workbook files.
Read-only workbook preview with clipped values and no formulas. Licensed buyers receive the full Evidence & Decision Workbook with editable assumptions and working files.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | Workbook Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Claim reconciliation, 168 audited = 89 kept. fields and clipped entries such as Customer-facing after de-duplication, 86 (2. |
| 2 | Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. Public preview exposes claim_id, primary, source_title, verdict fields and clipped entries such as K001, PMID:41296602, Prediction of antimicrobial.. |
| 3 | Source-Support Verdicts | Independent check on whether key claims are actually supported by cited sources. Public preview exposes claim_id, primary, verdict, verbatim_excerpt (from verified. fields and clipped entries such as K001, PMID:41296602, SUPPORTS_PARTIALLY. |
| 4 | Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes identifier, type, title, journal/sponsor fields and clipped entries such as DOI:10.1002/adma.202500043, DOI, AI‐Guided Design of Antimicrobial.. |
| 5 | Source Quality Summary | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. Public preview exposes Evidence-maturity anchor, Modal study:. fields from this sheet. |
| 6 | Countermeasure Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Modality, Cornering layer(s), Escapable/cornered, Max evidence model fields and clipped entries such as MALDI-TOF + ML diagnostics, Pathogen. |
| 7 | Cornering-Layer Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Cornering layer, What it controls, Evidence depth, Highest-leverage move fields and clipped entries such as Pathogen Resolution, Speed of. |
| 8 | Pathogen Strategy Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Pathogen (WHO BPPL 2024), Dominant clones, Favorable cornering lever., Caveat fields and clipped entries such as P. aeruginosa (High), -,. |
| 9 | Asset-Sponsor Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Asset / platform, Sponsor, Modality, Stage (verified) fields and clipped entries such as BX004 / BX004-A, BiomX, Inhaled phage (P. aeruginosa, CF). |
| 10 | Trial-Catalyst Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes NCT, title, sponsor, phase fields and clipped entries such as NCT06814756, Bacteriophage Therapy for Morganella., University of Calgary. |
| 11 | Resistance-Escape Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Mechanism / system, Type, Effect on cornering, Pathogen fields and clipped entries such as Collateral sensitivity., Evolutionary trade-off, Enables. |
| 12 | Diagnostic Performance Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Platform, Metric, Value (verified), Validation type fields and clipped entries such as MALDI-TOF + ML AMR, AUROC, ≥0.80 (one day earlier than. |
| 13 | Microbiome Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Finding, Mechanism, Effect, Model fields and clipped entries such as Anti-anaerobic antibiotics -> AKI, Gut anaerobe depletion, +61%. |
| 14 | Biomarker-Endpoint Map | Tracks biomarkers or readouts that determine whether the thesis is moving toward testable evidence. Public preview exposes Biomarker / readout, Links to endpoint, Maturity, Source fields and clipped entries such as MALDI-TOF-ML resistance prediction,. |
| 15 | Regulatory Tracker | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. Public preview exposes Modality, Pathway / channel, Status (June 2026), Binding evidence gap fields and clipped entries such as Antibacterials / AMPs, FDA. |
| 16 | Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes figure_id, file, anchor section, backend fields and clipped entries such as fig01_grade_recalibration, fig01_grade_recalibration.png,. |
| 17 | Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. Public preview exposes figure_id, status, backend, data_type fields and clipped entries such as fig01_grade_recalibration, PASS, deterministic. |
| 18 | Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. Public preview exposes #, id, tier, axis (layers) fields and clipped entries such as F1, Flagship, Cost-locked phage-antibiotic pair vs.. |
| 19 | Most Valuable Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. Public preview exposes #, Study, Question, Design / comparator fields and clipped entries such as Adaptive GN-BSI platform trial., Does the diagnosis-linked. |
| 20 | Verification-Search Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes ClinicalTrials.gov v2, Independent re-verification of 30., 30 resolved, all fields and clipped entries such as Crossref, Independent. |
| 21 | Excluded Claims | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes claim_id, set, disposition, reason fields and clipped entries such as O001, offtopic, EXCLUDE. |
| 22 | Salvage Ledger | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes REUSE, 89 kept claims + 96-source., Re-verified; 86 customer-facing. fields and clipped entries such as REUSE, Strategic recs,. |
| 23 | Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes hypothesis_id, study_id, endpoint, test_type fields and clipped entries such as F1, S-F1, Time to emergence of a defined.. |
| 24 | RCC_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Key (FEATURE|FORM), Feature, Canonical, w_CORNERED fields and clipped entries such as ESCAPE_HITS|1, ESCAPE_HITS, K1. |
| 25 | RCC_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes ESCAPE_HITS, Independent adaptations required., 1 / 2 / 3+ (or single, pair,., k from the k-integrity assay =. fields and clipped entries such as. |
| 26 | RCC_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes MATURITY, murine, MATURITY|MURINE, MURINE, 0 fields from this sheet. |
| 27 | RCC_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Evidence completeness (1-4), 2 fields and clipped entries such as Unresolved inputs flag, Collateral unmapped/cross flag. |
| 28 | RCC_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Escape-mechanism mapping., ESCAPE_HITS, Required fields and clipped entries such as Strain-level collateral-sensitivity., COLLATERAL, Required. |
| 29 | RCC_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Same cornered pair, but evidence., 2, verified, sparing fields and clipped entries such as Novel AI-designed monotherapy, none, intermediate. |
| 30 | RCC_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Functional endpoint, time-to-emergence of clinically. fields and clipped entries such as Calibration, required (reliability across., Weights. |
| 31 | RCC_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes RCC element, Maps to claim/finding, Evidence ID, Figure fields and clipped entries such as ESCAPE_HITS (k) feature, kf-treadmill;. |
| 32 | Traceability Certificate | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes claim_id, report_section, page_anchor (paginated TOC), claim_text fields and clipped entries such as K001, Limitations & Evidence Gaps,. |
| 33 | Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. Public preview exposes Translation risk, Countermeasure Scorecard, 0-4, 0 = de-risked/controlled; 4 =. fields and clipped entries such as RCC per-class weight,. |
| 34 | Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company, Asset / platform, Modality, Target / indication fields and clipped entries such as GSK, Gepotidacin (Blujepa), Oral topoisomerase. |
| 35 | Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes RCC classifier, v1.0 (expert-initialized), 8-sheet executable module;., - fields and clipped entries such as Evidence cutoff, June 13,. |
| 36 | Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes #, Issue, Status, Resolution fields and clipped entries such as AI-1, Workbook genuinely executable (live., RESOLVED. |
Power-calculated next studies
Power calculations are the execution bridge.
Power calculations are planning-grade research calculations for endpoint logic, assumptions, sample size, budget, and timeline. They do not prove hypotheses or constitute clinical protocol.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| F1 | Time to emergence of a defined resistance threshold (PRIMARY, time-to... | survival | 0.279 | 0.05 | 0.80 | 120 | 120 |
| F2 | Time-to-treatment-failure under cycling, by trade-off verification st... | two_proportion | 0.5 | 0.05 | 0.80 | 60 | 60 |
| R1 | Dual antibiotic-plus-phage failure, high vs low integron burden | two_proportion | 0.55 | 0.05 | 0.80 | 150 | 150 |
| F3 | AKI/secondary-infection composite (superiority co-primary); microbiol... | two_proportion | 0.2 | 0.05 | 0.80 | 1100 | 1100 |
| F4 | Phage re-sensitization (>=2-log load restored), Thoeris/anti-defense ... | two_proportion | 0.15 | 0.05 | 0.80 | 60 | 60 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 118-page report + 36-sheet workbook
Buy now
- Decision research report (118 pages, PDF)
- Evidence & Decision Workbook (36 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price